SAB Biotherapeutics (SABS) Convertible Debt (2022 - 2023)

SAB Biotherapeutics' (SABS) quarterly Convertible Debt came in at $541644.0 in Q2 2023, little changed on a QoQ basis from $541644.0 in Q1 2023.

SAB Biotherapeutics (SABS) Convertible Debt (2022 - 2023) Analysis & Trends

SAB Biotherapeutics (SABS) has 2 years of Convertible Debt data on file, last reported at $541644.0 in Q2 2023.

Quarterly Convertible Debt changed N/A year-over-year to $541644.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $541644.0 (changed N/A YoY) and the FY2022 annual result came in at $541644.0, changed N/A from the prior year.
Convertible Debt held at $541644.0 in Q2 2023, from $541644.0 in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $541644.0 in Q4 2022 to a low of $541644.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	SAB Biotherapeutics	308.92 Mn	308.92 Mn	-

Download Data